You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY22 is not expected to be complete until September, 2023.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
-
3D Printed Multifunctional Brain Windows for Simultaneous Optical Imaging and Electrophysiology
SBC: Applied Universal Dynamics, Corp. Topic: 107PROJECT SUMMARY This proposal responds to PAR-18-870 titled “BRAIN Initiative: Development Optimization, and Validation of Novel Tools and Technologies for Neuroscience Research (STTR).” This project is a Fast Track STTR with a phase I and phase II. The small business, Applied Universal Dynamics Corp. (AUD) is collaborating with the University of Minnesota (U of MN). The activity patterns of t ...
STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
Dynasore Analogues for Ocular Surface Protection
SBC: MEDCHEM PARTNERS LLC Topic: NEI7. PROJECT SUMMARY Diseases of the ocular surface are among the top reasons for visits to eye care practitioners. These conditions can severely affect eyesight and quality of life. Symptoms may include blurry vision, discomfort or pain, redness and itching, and in severe cases, blindness due to corneal scarring. Many ocular surface diseases are initiated by loss of tear film homeostasis and can be ...
STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
Pharmacologic Suppression of Reperfusion Injury Following Endovascular Thrombectomy In Stroke.
SBC: BIOMIMETIX JV LLC Topic: 102Ischemic stroke is a leading cause of death and disability in the United States. This often is attributable to thrombus formation at an atherosclerotic plaque or thromboembolism. Patients who present within 4.5 hours of symptom onset are eligible for thrombolysis with tissue plasminogen activator (tPA). This serves andlt;5% of victims. Recently, major advance has been made with proven efficacy fro ...
STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
Science Take-Out Kits for Improving Environmental Health Literacy on Vaping
SBC: Science Take-Out, LLC Topic: RABSTRACT This supplement project will expand on our current STTR Phase I project in which we partnered with University of Rochesterandapos;s Environmental Health Sciences Center to develop three Science Take-Out vaping education kits. Our vaping education kits involve students in using hands-on activities and real-life scenarios to investigate the harmful effects of chemicals used in e-cigarette f ...
STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
Extending WAAVES+: An animal and environment-agnostic, automated USV scoring platform for high-throughput social, behavioral, and neuropharmacological studies
SBC: CORNERSTONE RESEARCH GROUP INC Topic: 101Project SummaryUltrasonic vocalizations (USVs) are known to reflect emotional processing, brain neurochemistry and brain function - key observations in animal model studies. Collecting and processing USV data is time-intensive, manual, and costly. Most importantly, it limits researchers’ ability to employ fully effective, and nuanced experimental designs, and is a barrier to entry for other rese ...
STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
Good Bowls: Empowering Communities to Achieve Good Food Access and Health Equity
SBC: Equiti Foods, LLC Topic: 102Abstract Emerging data indicate that those with pre-existing health conditions, such as obesity, diabetes, and heart disease, are at significantly increased risk of contracting COVID-19, as are low income and persons of color. Research also suggests that food insecurity (lack of access to affordable, nutritionally valuable food) and poor dietary intake are likely contributors to health disparities ...
STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
Targeting bacteria, the innate response of the middle ear to infection, and host-pathogen interactions, using topical and transtympanic applications for the treatment of otitis media.
SBC: EARNANO LLC Topic: NICHDOtitis media is a world wide disease primarily affecting the pediatric population under the age ofyearsIt is the most common reason for pediatric care visits and antibiotic therapyOver prescription and poorcompliance have led to a reduced susceptibility of bacteria to antibiotics andconsequentiallyto recurrent and chronic ear diseasesClearlythere is a compelling need to investigate alternative the ...
STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
Mitigation of Radiation Therapy Induced Neuroinflammation and Cognitive Dysfunction
SBC: IMMUNOCHEM THERAPEUTICS LLC Topic: 102PROJECT SUMMARY Cognitive decline and deterioration of long term cognitive performance are major side effects of CNS cancer treatmentBrain metastases are the most common CNS malignancies and a common cause of morbidity and mortality in aboutof all cancer patients with systemic diseaseaffecting overpatients in the US annuallyAs most systemic chemotherapy agents do not cross the blood brain barriert ...
STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
Use of a Designer Proline-rich antimicrobial peptide Chaperone protein inhibitor (DPC) for treating antibiotic resistant pneumonia
SBC: Arrevus, Inc. Topic: NIAIDProject SummaryInfectious disease is the third leading cause of death in the United Statesand hospital acquired infectionsHAIsin particular affectmillion patients annuallyThe most common type of HAI is pneumoniaoften caused by multi drug resistantMDRpathogens such as Staphylococcus aureusPseudomonas aeruginosaKlebsiella pneumoniaeEscherichia coliand Acinetobacter baumanniiRates of antibiotic resis ...
STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
IRE1beta Inhibitors: Novel Therapeutics to Manage Excess Mucus in Asthma
SBC: Irex Pharma LLC Topic: NIAIDPROJECT SUMMARY Over 25 million Americans have asthma, which places an economic burden on the U.S. of $81.9 billion. Airway mucus overproduction is a hallmark of asthma, and the quantity and tenacity of mucus are increased during airway exacerbations. Mucolytics degrade mucus, but do not reduce its production. Although corticosteroids and other anti-inflammatory therapies indirectly decrease mucus ...
STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health